Demographics and treatment patterns of Turkish female HR (+) HER2 (-) mBC patients in real life setting

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/46630
• EU PAS number:
  EUPAS43182
• Study ID:
  46630
• Official title and acronym:
  Demographics and treatment patterns of Turkish female HR (+) HER2 (-) mBC patients in real life setting
• DARWIN EU® study:
  No
• Study countries:
  Türkiye
• Study description:
  To describe patient demographics, clinical and disease characteristics and treatment patterns of Hormone-receptor positive HR (+) HER2 (-) locally advanced and metastatic breast cancer (mBC) women treated in the routine practice setting in Turkey.
• Study status:
  Finalised

Research institutions and networks

Institutions

Pfizer

Multiple centres: 15 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 08/10/2021

Actual: 08/10/2021

Study start date

Planned: 20/10/2021

Actual: 25/10/2021

Date of final study report

Planned: 01/08/2022

Actual: 28/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer PFE İlaçları A.Ş.

Study protocol

Initial protocol

A5481172_Study_Protocol_V1

Updated protocol

A5481172_Study Protocol_V2

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable